Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
S243249
- Development stage
- Phase 2
- Lead developer
- Servier
- Modality
- Small Molecules
01
Overview
S243249 is a small molecule menin inhibitor being developed by Servier and its subsidiary Symphogen for the treatment of hematological malignancies, specifically Acute Myeloid Leukemia (AML) and Acute Lymphoblastic Leukemia (ALL). The drug works by disrupting the interaction between menin and its binding partners, such as MLL (KMT2A), which is a critical driver in leukemias characterized by MLL rearrangements or NPM1 mutations. By blocking these oncogenic complexes, S243249 aims to inhibit the expression of leukemogenic genes and promote differentiation of malignant cells. As of early 2026, the compound is in preclinical development.
- Other names
- Menin inhibitor S243249BN-104BN104BN 104
02
Targets
KMT2A
Beyond the preview
Go deeper on S243249.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on S243249.